[go: up one dir, main page]

MA31667B1 - Induction dun phenotype tolerogene dans des cellules dendritiques matures - Google Patents

Induction dun phenotype tolerogene dans des cellules dendritiques matures

Info

Publication number
MA31667B1
MA31667B1 MA32461A MA32461A MA31667B1 MA 31667 B1 MA31667 B1 MA 31667B1 MA 32461 A MA32461 A MA 32461A MA 32461 A MA32461 A MA 32461A MA 31667 B1 MA31667 B1 MA 31667B1
Authority
MA
Morocco
Prior art keywords
dendritic cells
tolerogeneous
phenotype
induction
mature dendritic
Prior art date
Application number
MA32461A
Other languages
Arabic (ar)
English (en)
Inventor
Herrera José M Carballido
Vries Jan E De
Ulf Korthaeuer
Maria Grazia Roncarolo
Silvia Adriana Gregori
Original Assignee
Novartis
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis, San Raffaele Centro Fond filed Critical Novartis
Publication of MA31667B1 publication Critical patent/MA31667B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation d'un molécule liant cd45 pour moduler la fonction de cellules dendritiques. La présente invention concerne notamment l'utilisation d'un molécule liant cd45 pour induire des cellules dendritiques tolérogènes, utiles dans le traitement de maladies telles que les maladies auto-immunes et le rejet de greffe.
MA32461A 2007-06-05 2009-12-30 Induction dun phenotype tolerogene dans des cellules dendritiques matures MA31667B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05
PCT/EP2008/056851 WO2008148761A1 (fr) 2007-06-05 2008-06-03 Induction d'un phénotype tolérogène dans des cellules dendritiques matures

Publications (1)

Publication Number Publication Date
MA31667B1 true MA31667B1 (fr) 2010-09-01

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32461A MA31667B1 (fr) 2007-06-05 2009-12-30 Induction dun phenotype tolerogene dans des cellules dendritiques matures

Country Status (17)

Country Link
US (1) US20100183602A1 (fr)
EP (1) EP2160410A1 (fr)
JP (1) JP2010529078A (fr)
KR (1) KR20100035643A (fr)
CN (1) CN101687928A (fr)
AU (1) AU2008258646A1 (fr)
BR (1) BRPI0812205A2 (fr)
CA (1) CA2689570A1 (fr)
CL (1) CL2008001620A1 (fr)
EA (1) EA200901621A1 (fr)
IL (1) IL202230A0 (fr)
MA (1) MA31667B1 (fr)
MX (1) MX2009013220A (fr)
TN (1) TN2009000494A1 (fr)
TW (1) TW200907061A (fr)
WO (1) WO2008148761A1 (fr)
ZA (1) ZA200908089B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
CA2768552A1 (fr) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programmation de cellules a des fins de therapie tolerogenique
EP2305277A1 (fr) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Utilisation de cellules dendritiques tolérogéniques dans le traitement et la prévention de l'athérosclérose
ES2773858T3 (es) 2010-10-06 2020-07-15 Harvard College Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
MX2013012596A (es) 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
WO2012167230A1 (fr) 2011-06-03 2012-12-06 President And Fellows Of Harvard College Vaccin anticancéreux de génération d'antigène in situ
US20130058976A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Allergen-specific induced tolerogenic dendritic cells for allergy therapy
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
BR112015027279A8 (pt) 2013-05-03 2018-01-30 Selecta Biosciences Inc métodos e composições para acentuar células t reguladoras cd4+
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
WO2016123573A1 (fr) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
EP3280464A4 (fr) 2015-04-10 2018-09-26 President and Fellows of Harvard College Dispositifs de piégeage de cellules immunitaires et leurs procédés de fabrication et d'utilisation
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018026884A1 (fr) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomatériaux pour moduler des réponses immunitaires
EP3592389B1 (fr) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Procédés et compositions associés à un traitement combiné avec anti-inflammatoires et nanovecteurs synthétiques comprenant un immunosuppresseur
JP2021524282A (ja) * 2018-05-17 2021-09-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ホスファターゼ動員による受容体の阻害
WO2020061129A1 (fr) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions et procédés de marquage et de modulation de cellules in vitro et in vivo
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20100035643A (ko) 2010-04-05
IL202230A0 (en) 2010-06-16
AU2008258646A1 (en) 2008-12-11
CA2689570A1 (fr) 2008-12-11
BRPI0812205A2 (pt) 2014-11-25
TN2009000494A1 (en) 2011-03-31
EA200901621A1 (ru) 2010-06-30
ZA200908089B (en) 2010-07-28
EP2160410A1 (fr) 2010-03-10
TW200907061A (en) 2009-02-16
CL2008001620A1 (es) 2009-02-20
US20100183602A1 (en) 2010-07-22
CN101687928A (zh) 2010-03-31
MX2009013220A (es) 2010-04-09
JP2010529078A (ja) 2010-08-26
WO2008148761A1 (fr) 2008-12-11

Similar Documents

Publication Publication Date Title
MA31667B1 (fr) Induction dun phenotype tolerogene dans des cellules dendritiques matures
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA34654B1 (fr) Variants silencieux de fc d'anticorps anti-cd40
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA33349B1 (fr) Compositions pharmaceutiques solides et procedes pour leur production
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
MX2009008174A (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA45504B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
MA33492B1 (fr) Inhibiteurs de bace
TW200801041A (en) Antibodies against human IL-22 and uses therefor
CO6341640A2 (es) \\\"tratamiento de enfermedad autoinmunitaria e inflamatoria\\\"
WO2007039150A3 (fr) Populations de cellules presentant une activite immunoregulatrice, procede pour isoler ces populations de cellules, et leurs utilisations
FR2938437B1 (fr) Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
MA31795B1 (fr) Molécules et méthodes pour moduler un constituant de complément
IL215026A (en) 1r7zb antagonist, methods and compounds @ which include @ the same
PL1836169T3 (pl) Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
FR2943249B1 (fr) Utilisation de la decorine pour augmenter la masse musculaire
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MX350813B (es) Composicion que comprende un surfactante no ionico y un polimero ionico.
MX2007005587A (es) Nueva composicion para facilitar el parto humano.